INSM vs RPRX: stock comparison and AI forecast
Insmed Inc (INSM) and Royalty Pharma Plc (RPRX) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
INSM Insmed Inc
- Price
- $114.41 +9.0% · 6M
- Market Cap
- $25.10B
- P/E Ratio
- –
- Size
- large-cap
- AI Forecast
RPRX Royalty Pharma Plc
- Market Cap
- $28.82B
- P/E Ratio
- 47.1x
- Size
- large-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Key facts
- RPRX is 1.1 times larger than INSM by market capitalization ($28.82B against $25.10B).
- RPRX turns 25.7% of its revenue into net income, against -39.9% for INSM.
- INSM carries 2.07 times debt per unit of equity, against 1.41 times for RPRX.
- RPRX yields 1.42% in dividends; INSM pays none.
- Both companies share the SEC industry classification Pharmaceutical Preparations.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | INSM | RPRX |
|---|---|---|
| Market Cap | $25.10B | $28.82B |
| P/E Ratio | – | 47.06x |
| P/B Ratio | 34.56x | 4.22x |
| Dividend Yield | – | 1.42% |
| EPS | $-2.01 | $1.43 |
| Book Value/Share | $3.31 | $15.96 |
| Revenue/Share | $6.93 | $6.11 |
| FCF/Share | $-2.86 | – |
Profitability & Margins
| Metric | INSM | RPRX |
|---|---|---|
| ROE | -83.4% | 9.8% |
| ROA | -27.2% | 3.5% |
| ROIC | -34.6% | 8.2% |
| Gross Margin | 84.4% | – |
| Operating Margin | -37.1% | 57.1% |
| Net Margin | -39.9% | 25.7% |
| EBT Margin | -39.4% | 44.8% |
| Tax Rate | -1.3% | 0.0% |
Financial Health
| Metric | INSM | RPRX |
|---|---|---|
| Current Ratio | 2.86x | 1.29x |
| Quick Ratio | 2.59x | – |
| D/E Ratio | 2.07x | 1.41x |
| Financial Leverage | 3.07x | 2.85x |
| Interest Coverage | -6.7x | 1.2x |
| Working Capital | $1.11B | $347M |
Cash Flow
| Metric | INSM | RPRX |
|---|---|---|
| Operating Cash Flow | -$596M | $2.96B |
| Free Cash Flow | -$628M | – |
| Capital Spending | -$32M | – |
| OCF Growth YoY | – | 23.1% |
| FCF/Sales | -41.3% | – |
| CapEx/Sales | 2.1% | – |
Operational Efficiency
| Metric | INSM | RPRX |
|---|---|---|
| Asset Turnover | 0.68x | 0.13x |
| Receivables Turnover | 5.9x | – |
| Inventory Turnover | 1.4x | – |
| Fixed Assets Turnover | 14.0x | – |
| Days Sales Outstanding | 62 days | – |
| Days Inventory | 252 days | – |
| Payables Period | 130 days | – |
| Cash Conversion Cycle | 185 days | – |
Income Statement
| Metric | INSM | RPRX |
|---|---|---|
| Total Revenue | $1.52B | $2.62B |
| Operating Income | -$564M | $1.50B |
| Net Income | -$606M | $671M |
| R&D Expense | $944M | $251M |
| SG&A Expense | $960M | – |
| Cost of Goods Sold | $237M | – |
Dividend & Shareholder Information
| Metric | INSM | RPRX |
|---|---|---|
| Dividends Per Share | – | $0.95 |
| Payout Ratio | – | 66.4% |
| Shares Outstanding | 219M | 428M |
| Net Income Growth | – | -12.2% |
| EPS Growth | – | 4.4% |
INSM vs RPRX: stock comparison and AI forecast
Which is bigger, INSM or RPRX?
RPRX is 1.1 times larger than INSM by market capitalization ($28.82B against $25.10B).
Which one does Intratio's AI model rank higher, INSM or RPRX?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.